Cargando…

Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis

PURPOSE: To estimate the cost-effectiveness and budget impact of viscosupplementation with one intra-articular (IA) injection of 6 mL hylan G-F 20 (Synvisc-One(®)) and with three injections of 2 mL hylan G-F 20 (Synvisc(®)3×2) in knee osteoarthritis (OA) patients compared with conventional support t...

Descripción completa

Detalles Bibliográficos
Autores principales: Migliore, Alberto, Integlia, Davide, Pompilio, Giuseppe, Di Giuseppe, Francesca, Aru, Cinzia, Brown, Tray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659788/
https://www.ncbi.nlm.nih.gov/pubmed/31413608
http://dx.doi.org/10.2147/CEOR.S194669
_version_ 1783439199114887168
author Migliore, Alberto
Integlia, Davide
Pompilio, Giuseppe
Di Giuseppe, Francesca
Aru, Cinzia
Brown, Tray
author_facet Migliore, Alberto
Integlia, Davide
Pompilio, Giuseppe
Di Giuseppe, Francesca
Aru, Cinzia
Brown, Tray
author_sort Migliore, Alberto
collection PubMed
description PURPOSE: To estimate the cost-effectiveness and budget impact of viscosupplementation with one intra-articular (IA) injection of 6 mL hylan G-F 20 (Synvisc-One(®)) and with three injections of 2 mL hylan G-F 20 (Synvisc(®)3×2) in knee osteoarthritis (OA) patients compared with conventional support therapy (CST – eg, NSAIDs and acetaminophen) and the cost-effectiveness of one IA injection of 2 mL hylan G-F 20 (Synvisc(®)1×2) in hip OA patients compared with CST from an Italian Health System perspective. METHODS: The model used was a Markov model with states for stages II–IV on the Kellgren–Lawrence scale and runs on 6-month cycles over a 5-year time horizon. A 3.5% discount was applied to both costs and utilities. Direct costs were determined from the perspective of the Italian National Health Service. A one-way and probabilistic sensitivity analysis was conducted for both comparisons. RESULTS: Hylan G-F 20 1×6 mL and hylan G-F 20 3×2 mL for knee OA were very likely to be cost-effective when compared to acetaminophen (ICER = €3,160.61 and €3,845.81 per QALY, respectively) and NSAIDs as both ICERs are below €25,000. The hip OA treatment by hylan G-F 20 1×2 mL was dominant compared to NSAIDs and very likely compared to acetaminophen. The results of the cost-effectiveness analysis were confirmed by one-way sensitivity analysis. The budget impact analysis for knee and hip OA showed a small increase in expenditure during 5 years. CONCLUSIONS: Hylan G-F 20 1×6 mL/hylan G-F 20 is a cost-effectiveness treatment compared to NSAIDs and acetaminophen in the treatment of knee/hip OA in Italy. The treatment of hip and knee OA resulted in cost-saving with hylan G-F 20 1×2 mL and economically sustainable with hylan G-F 20 1×6 mL. However, Real Word Evidence studies should be conducted in order to estimate costs associated with both prosthetics and to understand the reduction of physiotherapy and medication due to hylan G-F 20.
format Online
Article
Text
id pubmed-6659788
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66597882019-08-14 Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis Migliore, Alberto Integlia, Davide Pompilio, Giuseppe Di Giuseppe, Francesca Aru, Cinzia Brown, Tray Clinicoecon Outcomes Res Original Research PURPOSE: To estimate the cost-effectiveness and budget impact of viscosupplementation with one intra-articular (IA) injection of 6 mL hylan G-F 20 (Synvisc-One(®)) and with three injections of 2 mL hylan G-F 20 (Synvisc(®)3×2) in knee osteoarthritis (OA) patients compared with conventional support therapy (CST – eg, NSAIDs and acetaminophen) and the cost-effectiveness of one IA injection of 2 mL hylan G-F 20 (Synvisc(®)1×2) in hip OA patients compared with CST from an Italian Health System perspective. METHODS: The model used was a Markov model with states for stages II–IV on the Kellgren–Lawrence scale and runs on 6-month cycles over a 5-year time horizon. A 3.5% discount was applied to both costs and utilities. Direct costs were determined from the perspective of the Italian National Health Service. A one-way and probabilistic sensitivity analysis was conducted for both comparisons. RESULTS: Hylan G-F 20 1×6 mL and hylan G-F 20 3×2 mL for knee OA were very likely to be cost-effective when compared to acetaminophen (ICER = €3,160.61 and €3,845.81 per QALY, respectively) and NSAIDs as both ICERs are below €25,000. The hip OA treatment by hylan G-F 20 1×2 mL was dominant compared to NSAIDs and very likely compared to acetaminophen. The results of the cost-effectiveness analysis were confirmed by one-way sensitivity analysis. The budget impact analysis for knee and hip OA showed a small increase in expenditure during 5 years. CONCLUSIONS: Hylan G-F 20 1×6 mL/hylan G-F 20 is a cost-effectiveness treatment compared to NSAIDs and acetaminophen in the treatment of knee/hip OA in Italy. The treatment of hip and knee OA resulted in cost-saving with hylan G-F 20 1×2 mL and economically sustainable with hylan G-F 20 1×6 mL. However, Real Word Evidence studies should be conducted in order to estimate costs associated with both prosthetics and to understand the reduction of physiotherapy and medication due to hylan G-F 20. Dove 2019-07-22 /pmc/articles/PMC6659788/ /pubmed/31413608 http://dx.doi.org/10.2147/CEOR.S194669 Text en © 2019 Migliore et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Migliore, Alberto
Integlia, Davide
Pompilio, Giuseppe
Di Giuseppe, Francesca
Aru, Cinzia
Brown, Tray
Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis
title Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis
title_full Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis
title_fullStr Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis
title_full_unstemmed Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis
title_short Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis
title_sort cost-effectiveness and budget impact analysis of viscosupplementation with hylan g-f 20 for knee and hip osteoarthritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659788/
https://www.ncbi.nlm.nih.gov/pubmed/31413608
http://dx.doi.org/10.2147/CEOR.S194669
work_keys_str_mv AT migliorealberto costeffectivenessandbudgetimpactanalysisofviscosupplementationwithhylangf20forkneeandhiposteoarthritis
AT integliadavide costeffectivenessandbudgetimpactanalysisofviscosupplementationwithhylangf20forkneeandhiposteoarthritis
AT pompiliogiuseppe costeffectivenessandbudgetimpactanalysisofviscosupplementationwithhylangf20forkneeandhiposteoarthritis
AT digiuseppefrancesca costeffectivenessandbudgetimpactanalysisofviscosupplementationwithhylangf20forkneeandhiposteoarthritis
AT arucinzia costeffectivenessandbudgetimpactanalysisofviscosupplementationwithhylangf20forkneeandhiposteoarthritis
AT browntray costeffectivenessandbudgetimpactanalysisofviscosupplementationwithhylangf20forkneeandhiposteoarthritis